Vnitr Lek 2020, 66(6):371-377 | DOI: 10.36290/vnl.2020.104

Crystalopathy - underestimated entity in nephrology

Petra Bachroňová, Ivan Rychlík
I. interní klinika 3. LF UK a FN Královské Vinohrady Praha

Crystal is a solid particle with a geometric shape because its atoms, ions, or molecules are arranged in a regular ordered structure. However, in case of accidental order of the particles, we are talking about the amorphous substances which can also form crystal-like particles. Crystallopathy is a disease that involves crystals of crystal-like particulate matter in the pathogenesis of tissue injury. Generally, several predominant pathophysiological mechanisms are involved in the formation of crystallopathies: necroinflammation, chronic remodeling of tissues leading to their atrophy and scarring, and obstruction of ducts, cavities or vessels by larger crystalline masses or stones. The basic distribution of crystallopathies in nephrology is as follows: renovascular crystallopathy (type 1), tubular crystallopathy (type 2), and finally urolithiasis (type 3) (tab. 1). Nowadays, the issue of crystallopathies in general medicine is omitted frequently not only among a wide range of professionals in the field of internal medicine but also in the field of specialists - nephrologists, urologist etc. One of the possible reasons may be the complexity and difficulty of grasping a wide-ranging topic, so it is our intention to provide an overview of the latest findings and possible approaches to this problem.

Keywords: hyperuricemia, cholesterol embolism, crystallopathy, oxalate, tubulointerstitial nephritis, urolithiasis.

Published: October 8, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bachroňová P, Rychlík I. Crystalopathy - underestimated entity in nephrology. Vnitr Lek. 2020;66(6):371-377. doi: 10.36290/vnl.2020.104.
Download citation

References

  1. Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystal‑induced kidney injury. Nat Rev Nephrol 2017; 13: 226-240. Go to original source... Go to PubMed...
  2. Mulay SR, Anders HJ. Crystallopathies. N Engl J Med 2016; 374: 2465-2476. Go to original source... Go to PubMed...
  3. Venturelli Ch, Jeannin G, Sottini L, et al. Cholesterol crystal embolism (atheroembolism). Heart Int 2006; 2: 155. Go to original source... Go to PubMed...
  4. Herlitz LC, D'Agati VD, Markowitz GS. Crystalline nephropathies. Arch Pathol Lab Med 2012; 136: 713-720. Go to original source... Go to PubMed...
  5. Doshi M, Lahoti A, Danesh FR, et al. Paraprotein‑Related Kidney Disease: Kidney Injury from Paraproteins‑What Determines the Site of Injury? Clin J Am Soc Nephrol 2016; 11: 2288-2294. Go to original source... Go to PubMed...
  6. Howard SC, Jones DP, Pui ChH. The Tumor Lysis Syndrome. N Engl J Med 2011; 364: 1844-1854. Go to original source... Go to PubMed...
  7. Robijn S, Hoppe B, Vervaet BA, et al. Hyperoxaluria: a gut‑kidney axis? Kidney Int 2011; 80: 1146-1158. Go to original source... Go to PubMed...
  8. Nazzal L, Puri S, Goldfarb DS Enteric hyperoxaluria: an important cause of end‑stage kidney disease. Nephrol Dial Transplant 2015; 31: 375-382. Go to original source... Go to PubMed...
  9. van Slambrouck CM, Salem F, Meehan MM, et al. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int 2013; 84: 192-197. Go to original source... Go to PubMed...
  10. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361: 62-72.Další literatura u autorkya na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
  11. Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: Pathogenesis, Diagnosis, and Treatment. Ochsner J 2015; 15: 58-69.
  12. Vanholder R, Sever MS, Erek E, et al. Rhabdomyolysis. J Am Soc Nephrol 2000; 11: 1553-1561. Go to original source... Go to PubMed...
  13. Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009; 67: 272-283.
  14. (Guideline) Agency for Toxic Substances and Disease Registry. Medical Management Guidelines for Ethylene Glycol. ATSDR. Available at https://www.atsdr.cdc.gov/mmg/mmg.asp?id=82 & tid=21. October 21, 2014; Accessed: September 25, 2017.
  15. Hoffmanová I, Anděl M. Závažná rizika spojená s užíváním natrium‑fosfátových projímadel. Vnitř Lék 2013; 59: 1111-1116. Go to PubMed...
  16. Markowitz GS, Stokes MB, Radhakrishnan J, et al. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005; 16: 3389-3396. Go to original source... Go to PubMed...
  17. Gagnon RF, Alli AI, Watters AK, et al. Indinavir crystalluria. Kidney Int 2006; 70: 2047. Go to original source... Go to PubMed...
  18. Matlaga BR, Shah OD, Assimos DG. Drug‑induced urinary calculi. Rev Urol 2003; 5: 227-231. Go to PubMed...
  19. EAU Guidelines. Edn. presented at the EAU Annual Congress London 2018. ISBN 978-94-92671-01-1. EAU Guidelines Office, Arnhem, The Netherlands. http://uroweb.org/guidelines/compilations‑of‑all‑guidelines/.
  20. Sayer JA. Progress in Understanding the Genetics of Calcium‑Containing Nephrolithiasis. J Am Soc Nephrol 2017; 28: 748-759. Go to original source... Go to PubMed...
  21. Mulay SR, Shi C, Ma X, et al. Novel Insights into Crystal‑Induced Kidney Injury. Kidney Dis (Basel) 2018; 4: 49-57. Go to original source... Go to PubMed...
  22. Bazin D, Letavernier E, Jouanneau CH, et al. New insights into the presence of sodium hydrogen urate monohydrate in Randall's plaque. Comptes Rendus Chimie, Elsevier Masson 2016; 19: 1456-1460. Go to original source...
  23. Johnson RJ, Feehally J, Floege J. Comprehensive clinical nephrology. 5th ed. Saunders, an imprint of Elsevier Inc. 2015, 760 s.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.